openPR Logo
Press release

Global Controlled Drug Delivery Market Sales Revenue Clinical Trials Pipeline Report 2022

06-30-2017 09:11 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Controlled Drug Delivery Market Sales Revenue Clinical

“Global Controlled Drug Delivery Market and Clinical Trial Outlook 2022” report gives comprehensive clinical and non-clinical insight on the emergence and integration of controlled release technology in the drug delivery. Report highlights the ongoing development of more than 300 controlled release drugs in clinical trials and helps to analyze the existing clinical mechanism of 133 commercially available controlled release drugs in the market. The fundamentals and application of controlled release drug delivery encapsulated in the report helps to identify the various aspect of the growing controlled release drug delivery market.

Download Report:

https://www.kuickresearch.com/report-global-controlled-drug-delivery-market-and-clinical-trial-outlook-2022.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"Global Controlled Drug Delivery Market and Clinical Trial Outlook 2022"

1 Drug Delivery: An Advancing Trajectory
1.1 Preface Towards Drug Delivery
1.2 Idealism of Drug Delivery System

2. Introduction to Controlled Drug Delivery
2.1 Novel Drug Delivery Systems
2.2 Preamble to Controlled Drug Delivery

3. Evolution of Controlled Drug Delivery
3.1 First Generation
3.2 Second Generation

4. Fundamentals of Controlled Drug Delivery
4.1 Prerequisites of Controlled Delivery
4.2 Rationale for Controlled Drug Delivery

5. Mechanism of Controlled Drug Release
5.1 Diffusion Controlled
5.2 Dissolution Controlled System
5.3 Water Penetration Controlled System
5.4 Erosion Controlled System
5.5 Ion-Exchange Controlled System

6. Cataloging of Controlled Drug Delivery
6.1 Classification Based Over Delivery Systems
6.2 Classification Based Over Technicality
6.3 Classification Based Over Routes

7. Approaches for Controlled Drug Delivery
7.1 Polymers
7.2 Chronopharmaceutics
7.3 Nanoparticulate Delivery System

8. Global Controlled Release Drug Clinical Pipeline Overview
8.1 Phase
8.2 Country/Region
8.3 Mode of Action
8.4 Drug class
8.5 Indication

9. Application of Controlled Drug Delivery
9.1 Diabetes
9.2 Cancer
9.3 Cardiovascular Diseases
9.4 Neurological Disorders
9.5 Infections

10. Drug Designing for Controlled Delivery
10.1 Enteral Dosage Formulations
10.1.1 Solid Dosage Forms
10.1.2 Liquid Dosage Forms
10.1.3 Inhalation Dosage Forms
10.2 Parenteral Dosage Forms
10.2.1 Injectable Dosage Forms
10.2.2 Implantable Device
10.3 General Mechanisms of Drug Release

11. Market Inclinations
11.1 Market over Routes of Administration
11.2 Market over Approaches

12. Global Controlled Drug Delivery Market Dynamics
12.1 Accelerative Parameters
12.2 Challenges

13. Global Controlled Drug Delivery Market Future Outlook
13.1 Ongoing Clinical Trials
13.2 Future Market Opportunities

14. Global Controlled Drug Delivery Clinical Trials by Company, Indication and Phase
14.1 Unknown
14.2 Research
14.3 Preclinical
14.4 Clinical
14.5 Phase-I
14.6 Phase-I/II
14.7 Phase-II
14.8 Phase-II/III
14.9 Phase-III
14.10 Preregistration
14.11 Registered

15. Marketed Controlled Release Clinical Insight by Company, Indication and Phase

16. Competitive Landscape
16.1 Allergan
16.2 Amylin Pharmaceuticals
16.3 AstraZeneca
16.4 BioAlliance Pharma
16.5 Biogen
16.6 Collegium Pharmaceutical
16.7 Controlled Therapeutics (Ferring Pharmaceuticals)
16.8 Cosmo Pharmaceuticals
16.9 Egalet
16.10 Elan Corporation
16.11 Encore Therapeutics
16.12 Flamel Technologies
16.13 GlaxoSmithKline
16.14 Heron Therapeutics
16.15 iCeutica
16.16 Mithra Pharmaceuticals
16.17 Neurim Pharmaceuticals
16.18 Novartis
16.19 Orexigen Therapeutics
16.20 Otsuka Pharmaceutical
16.21 Pfizer
16.22 Purdue Pharma
16.23 Syntex Pharmaceuticals International
16.24 Takeda
16.25 Zealand Pharma

Figure 1-1: Characteristics of an Ideal drug Delivery System
Figure 2-1: Limitations of the Conventional Drug Delivery Systems
Figure 2-2: Diversification of the Novel Drug Delivery Platforms
Figure 3-1: History of Drug Delivery Technology from First Generation till Third Generation
Figure 3-2: Barriers to be Overcome by the Third Generation Drug Delivery System
Figure 4-1: Demonstration of the Targeted and Non-Targeted Drug Delivery
Figure 4-2: Controlled Drug Release is by Zero Order Mechanism
Figure 5-1: Differentiation of the Two Forms of the Diffusion Controlled Mechanisms
Figure 5-2: Mechanism of Encapsulation Dissolution Controlled System
Figure 5-3: Osmotic Release of the Drug Delivery with the Controlled Mechanism
Figure 5-4: Illustration of Erosion Mechanisms Found in Matrix Systems
Figure 6-1: Plasma Concentration v/s Time Profile in Conventional and Controlled Release
Figure 6-2: Comparison of Varied Modified Drug Release Systems
Figure 6-3: Illustration of Mechanism of Pulsatile Drug Release in Pulsincap
Figure 6-4: Classification Based Over the Technicality Erudition
Figure 6-5: Structural Differentiation among Varied Classified Drug Delivery Systems
Figure 6-6: Classification Based over the Route of Administration
Figure 7-1: Categorization of Polymeric Controlled Drug Delivery Devices
Figure 7-2: Varied Nanostructures Available for the Nanoparticulate Delivery System
Figure 8-1: Global - Controlled Release Drug Clinical Pipeline by Phase (%), 2017 till 2022
Figure 8-2: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 8-3: Global - Controlled Release Drug Clinical Pipeline by Phase (%),2017 till 2022
Figure 8-4: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 8-5: Global - Controlled Release Drug Clinical Pipeline by Country/Region (Number),2017 till 2022
Figure 8-6: Global - Controlled Release Clinical Drug Pipeline by Mode of Action (Number), 2017 till 2022
Figure 8-7: Global - Controlled Release Drug Clinical Pipeline by Drug Class (Number), 2017 till 2022
Figure 8-8: Global - Controlled Release Drug Clinical Pipeline by indication (Number), 2017 till 2022
Figure 9-1: Major Non-Invasive Administrative Routes of Insulin Delivery
Figure 9-2: Layout of the Controlled Drug Delivery Approaches in Cancer Therapeutics
Figure 9-3: Controlled Drug Delivery Approaches used to Deliver Drugs to CNS
Figure 10-1: Dosage Formulations for the Controlled Drug Delivery
Figure 10-2: Mechanism of the Controlled Drug Release of the Solid Dosage Forms
Figure 10-3: Representation of Categories of Liquid Dosage Form
Figure 10-4: Mechanism of Controlled Delivery of Parenteral Dosage Forms
Figure 10-5: General Forms of Oral Controlled Release System Mechanism
Figure 10-6: Schematic Diffusion Controlled Drug Release from Inert Matrices
Figure 10-7: Demonstration of the Osmotic Pump Drug Release Mechanism
Figure 11-1: Drug Delivery Share by Route of Administration, 2016
Figure 11-2: Global - Oral Drug Delivery Administration Market (US$ Billion), 2016 and 2022
Figure 11-3: Global - Injectable Drug Delivery Systems Market (US$ Billion), 2016 and 2022
Figure 11-4: Global - Implantable Device Market (US$ Billion), 2016 and 2022
Figure 11-5: Global - Topical Drug Delivery System Market (US$ Billions), 2016 and 2022
Figure 11-6: Global - Biodegradable Polymer Market (US$ Billions), 2016 and 2022
Figure 11-7: Global - Smart Polymers Market (US$ Billion), 2016 and 2022
Figure 11-8: Global - Nanomedicine Market (US$ Billion), 2016-2022
Figure 12-1: Accelerative Parameters of Controlled Drug Delivery Systems
Figure 12-2: Major Challenges Faced by Controlled Drug Delivery System
Figure 13-1: Illustration of Clinical Trials in Varied Segments for Controlled Drug Delivery

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Controlled Drug Delivery Market Sales Revenue Clinical Trials Pipeline Report 2022 here

News-ID: 603225 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug